Dilon Diagnostics has reported that its GammaLoc gamma-guided biopsy system is being implemented around the world as an accessory to the Dilon 6800 Gamma Cameras in North and Central America, Europe, the Middle East and Asia.
Dilon Diagnostics said that the GammaLoc system accessory complements the Dilon 6800 Gamma Camera, which is optimised to perform Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI).
As a follow-up to mammography, BSGI utilizes the Dilon 6800 Gamma Camera to help physicians see the breast more clearly and differentiate benign from malignant tissue, the company said.
The US Food and Drug Administration (FDA) granted 510(k) clearance for the GammaLoc lesion-localization system for molecular imaging biopsy guidance in December 2009.
MRI biopsy requires the patient to remain in the prone position during time-consuming sequences obtained before and after targeting, often resulting in substantial patent discomfort.
The GammaLoc allows for upright breast biopsies with optimal patient comfort and the entire system is small and portable, allowing physicians to perform molecular imaging guided biopsy procedures anywhere on site.
The entire system is small and portable, allowing physicians to perform molecular imaging guided biopsy procedures anywhere on site.
Dilon Diagnostics president and CEO Robert Moussa said that data consistently demonstrates that BSGI helps the physician pinpoint diagnosis for optimal treatment planning and GammaLoc further strengthens Dilon’s mission to provide innovative ways to continue the fight against breast cancer.